A combination of spironolactone, pioglytopon and metformin, taken in certain quantities, is used for the prevention or treatment of polycystic ovary syndrome, for the prophylaxis or treatment of low ovulation rate relating to hepatic steatosis n adolescent girls or women of childbearing age, as ...
found that pharmacological treatment with PFT-α reduced DIO-induced hepatic steatosis by reducing miR-34a, which was followed by increased expression of SIRT1 and enhanced PPARα transcriptional activation [95]. Moreover, miR-34a contributes to the development of hepatic steatosis by directly ...
(Fig.4g), improve glucose tolerance, and improve hepatic steatosis (Fig.4h, i), demonstrating the potential for FSH treatment to improve the symptoms of metabolic syndrome. Plasma triglyceride levels were significantly reduced in the FSH-treated group when compared to controls while cholesterol ...
Nonalcoholic fatty liver disease (NAFLD), defined as the presence of steatosis in > 5% of hepatocytes in the absence of alcohol abuse and other known causes of liver disease1, is estimated to affect approximately 25% of the human population worldwide2,3and may soon overtake hepatic C as...
Livers from the E fergusonii treatment group were larger in size and appeared pale in color compared with the con+saline group. We also detected lipid droplet accumulation, hepatomegaly, and hepatocellular ballooning in the E fergusonii group (Figure 3A). Steatosis and the hepatocellular ballooning...
Saying yes to obese living liver donors: Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Nakamuta M, Morizono S, Soejiima Y, ... JD.Perkins - 《Liver Transplantation》 被引量: 0发表: 2006年 Saying "yes" to obese living liver donors:...
Background: Previous studies have suggested that platelets are associated with inflammation and steatosis and may play an important role in liver health. Therefore, we evaluated whether antiplatelet agents can improve metabolic disorder-related fatty liv
Furthermore, it has been recently demonstrated that SIRT2 prevents liver steatosis by deacetylating the transcription factor hepatocyte nuclear factor 4α (HNF4α) [23]. However, the putative role of SIRT2 in the regulation of hepatic steatosis and the interplay with ER stress has not been ...
Non-alcoholic fatty liver disease (NAFLD) ranges from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH, which is accompanied by increased oxidative stress and inflammation in the liver, is associated with hepatic carcinogenesis. Green tea c
Alcoholic fatty liver (AFL) is a liver disease caused by long-term excessive drinking and is characterized by hepatic steatosis. Understanding the regulatory mechanism of steatosis is essential for the treatment of AFL. Rev-erbα is a member of the Rev-erbs family of nuclear receptors, playing ...